Guobang Pharma Ltd
SSE:605507
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guobang Pharma Ltd
Net Issuance of Debt
Guobang Pharma Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Guobang Pharma Ltd
SSE:605507
|
Net Issuance of Debt
¥218.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Issuance of Debt
-¥22.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Issuance of Debt
-¥4.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Issuance of Debt
¥26.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Net Issuance of Debt
-¥916.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Issuance of Debt
¥1.5B
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Guobang Pharma Ltd
Glance View
Guobang Pharma Ltd. has carved its niche within the pharmaceutical industry as an integrated player blending advanced chemical synthesis with pharmaceutical manufacturing. At its core, the company thrives on the development and production of active pharmaceutical ingredients (APIs), which are crucial components for a multitude of medications. Leveraging a robust research and development framework, Guobang Pharma consistently delivers high-quality APIs to both domestic and international clients, ensuring a steady flow of income. This strategic approach, combining a focus on innovative technology and stringent quality control, positions the company as a reliable partner in the global pharmaceutical supply chain. In addition to API production, Guobang Pharma extends its business model through the formulation and manufacturing of finished pharmaceutical products. By operating across this entire value chain, Guobang can capture a larger slice of the industry's revenue pie. The company’s diversified portfolio not only includes essential medicines but also specialty and generic drugs, allowing it to navigate market shifts and regulatory landscapes adeptly. This vertical integration enhances its competitive advantage by reducing dependency on external suppliers while contributing to its bottom line growth, as it fulfills varied market demands from development to distribution.
See Also
What is Guobang Pharma Ltd's Net Issuance of Debt?
Net Issuance of Debt
218.2m
CNY
Based on the financial report for Dec 31, 2025, Guobang Pharma Ltd's Net Issuance of Debt amounts to 218.2m CNY.
What is Guobang Pharma Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
22%
The average annual Net Issuance of Debt growth rates for Guobang Pharma Ltd have been -24% over the past three years , 22% over the past five years .